Literature DB >> 12542793

Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex.

K Le Blanc1, L Tammik, B Sundberg, S E Haynesworth, O Ringdén.   

Abstract

We aimed to study the effects of mesenchymal stem cells (MSCs) on alloreactivity and effects of T-cell activation on human peripheral blood lymphocytes (PBLs) in vitro. MSCs were expanded from the bone marrow of healthy subjects. MSCs isolated from second to third passage were positive for CD166, CD105, CD44, CD29, SH-3 and SH-4, but negative for CD34 and CD45. MSCs cultured in osteogenic, adipogenic or chondrogenic media differentiated, respectively, into osteocytes, adipocytes or chondrocytes. MSC added to PBL cultures had various effects, ranging from slight inhibition to stimulation of DNA synthesis. The stimulation index (SI = (PBL + MSC)/PBL) varied between 0.2 and 7.3. The SI was not affected by the MSC dose or by the addition of allogeneic or autologous MSCs to the lymphocytes. Suppression of proliferative activity was observed in all experiments after the addition of 10,000-40,000 MSCs to mixed lymphocyte cultures (MLCs). Lymphocyte proliferation was 10-90%, compared with a control MLC run in parallel without MSCs. In contrast, the addition of fewer MSCs (10-1000 cells) led to a less consistent suppression or a marked lymphocyte proliferation in several experiments, ranging from 40 to 190% of the maximal lymphocyte proliferation in control MLCs. The ability to inhibit or stimulate T-cell alloresponses appeared to be independent of the major histocompatibility complex, as results were similar using 'third party' MSCs or MSCs that were autologous to the responder or stimulating PBLs. The strongest inhibitory effect was seen if MSCs were added at the beginning of the 6 day culture, and the effect declined if MSCs were added on day 3 or 5. Marked inhibitory effects of allogeneic and autologous MSCs (15,000) were also noted after mitogenic lymphocyte stimulation by phytohaemagglutinin (median lymphocyte proliferation of 30% of controls), Concanavalin A (56%) and protein A (65%). Little, if any, inhibition occurred after stimulation with pokeweed mitogen. Low numbers of MSCs (150 cells) were unable to inhibit mitogen-induced T-cell responses. MSCs have significant immune modulatory effects on MLCs and after mitogenic stimulation of PBL. High numbers of MSCs suppress alloreactive T cells, whereas very low numbers clearly stimulated lymphocyte proliferation in some experiments. The effect of a larger number of MSCs on MLCs seems more dependent on cell dose than histocompatibility and could result from an 'overload' of a stimulatory mechanism.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12542793     DOI: 10.1046/j.1365-3083.2003.01176.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  378 in total

1.  Allogeneic mesenchymal stem cells do not protect NZBxNZW F1 mice from developing lupus disease.

Authors:  M Youd; C Blickarz; L Woodworth; T Touzjian; A Edling; J Tedstone; M Ruzek; R Tubo; J Kaplan; T Lodie
Journal:  Clin Exp Immunol       Date:  2010-04-29       Impact factor: 4.330

2.  Canine bone marrow-derived mesenchymal stromal cells suppress alloreactive lymphocyte proliferation in vitro but fail to enhance engraftment in canine bone marrow transplantation.

Authors:  Won Sik Lee; Yasuhiro Suzuki; Scott S Graves; Mineo Iwata; G M Venkataraman; Marco Mielcarek; Laura J Peterson; Susumu Ikehara; Beverly Torok-Storb; Rainer Storb
Journal:  Biol Blood Marrow Transplant       Date:  2010-05-10       Impact factor: 5.742

3.  Melatonin augments apoptotic adipose-derived mesenchymal stem cell treatment against sepsis-induced acute lung injury.

Authors:  Hong-Hwa Chen; Chia-Lo Chang; Kun-Chen Lin; Pei-Hsun Sung; Han-Tan Chai; Yen-Yi Zhen; Yi-Ching Chen; Ying-Chung Wu; Steve Leu; Tzu-Hsien Tsai; Chih-Hung Chen; Hsueh-Wen Chang; Hon-Kan Yip
Journal:  Am J Transl Res       Date:  2014-10-11       Impact factor: 4.060

4.  Human embryonic stem cell-derived mesenchymal stromal cells.

Authors:  Peiman Hematti
Journal:  Transfusion       Date:  2011-11       Impact factor: 3.157

5.  Multipotent Mesenchymal Stromal Cells for Autoimmune Diseases.

Authors:  Alan Tyndall
Journal:  Transfus Med Hemother       Date:  2008-07-17       Impact factor: 3.747

6.  Intranasal delivery of central nervous system-retargeted human mesenchymal stromal cells prolongs treatment efficacy of experimental autoimmune encephalomyelitis.

Authors:  Moa Fransson; Elena Piras; Hao Wang; Joachim Burman; Ida Duprez; Robert A Harris; Katarina LeBlanc; Peetra U Magnusson; Eva Brittebo; Angelica S I Loskog
Journal:  Immunology       Date:  2014-07       Impact factor: 7.397

Review 7.  Progress of mesenchymal stem cell therapy for neural and retinal diseases.

Authors:  Tsz Kin Ng; Veronica R Fortino; Daniel Pelaez; Herman S Cheung
Journal:  World J Stem Cells       Date:  2014-04-26       Impact factor: 5.326

8.  [Allogenic transplantation of human mesenchymal stem cells for tissue engineering purposes: an in vitro study].

Authors:  P Niemeyer; A Seckinger; H G Simank; P Kasten; N Südkamp; U Krause
Journal:  Orthopade       Date:  2004-12       Impact factor: 1.087

9.  Do cryopreserved mesenchymal stromal cells display impaired immunomodulatory and therapeutic properties?

Authors:  Guido Moll; Jessica J Alm; Lindsay C Davies; Lena von Bahr; Nina Heldring; Lillemor Stenbeck-Funke; Osama A Hamad; Robin Hinsch; Lech Ignatowicz; Matthew Locke; Helena Lönnies; John D Lambris; Yuji Teramura; Kristina Nilsson-Ekdahl; Bo Nilsson; Katarina Le Blanc
Journal:  Stem Cells       Date:  2014-09       Impact factor: 6.277

Review 10.  Mesenchymal stem cell treatments in rheumatology: a glass half full?

Authors:  Alan Tyndall
Journal:  Nat Rev Rheumatol       Date:  2013-11-12       Impact factor: 20.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.